Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pelthos Therapeutics ( (PTHS) ) just unveiled an announcement.
On December 23, 2025, Pelthos Therapeutics acquired from Australian biotech Hatchtech all rights and related assets to Xeglyze (abametapir), an FDA-approved topical prescription treatment for head lice, for a total purchase price of $1.8 million, following an earlier $450,000 down payment in November 2025 and completion of the transaction by the scheduled closing date of December 29, 2025. The deal gives Pelthos worldwide commercialization rights to the patent-protected pediculicide without future milestone or royalty obligations, adding a complementary, single-application head-lice therapy with both ovicidal and lousicidal activity to its portfolio and strengthening its commercial infrastructure in dermatology-related conditions, with plans to relaunch the product in 2027 and potentially expand its presence in a sizable pediatric head-lice market.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
More about Pelthos Therapeutics
Pelthos Therapeutics Inc. (NYSE American: PTHS) is a biopharmaceutical company focused on commercializing innovative therapeutic products that address unmet treatment burdens, led by its FDA-approved topical gel ZELSUVMI (berdazimer) for molluscum contagiosum, approved in 2024, and targeting niche dermatological and infection-related conditions.
Average Trading Volume: 23,778
Technical Sentiment Signal: Strong Buy
Current Market Cap: $95.69M
Find detailed analytics on PTHS stock on TipRanks’ Stock Analysis page.